Trump Administration Strikes Deal With Pfizer Aimed At Lowering Prescription Drug Prices

Pfizer and the White House announced an agreement with the Trump Administration to ensure lower prices for prescription medicines for U.S. consumers. The stated purpose of the agreement is to bring American drug prices in line with the lowest prices paid by other developed nations (known as the most-favored-nation, or MFN, price). More than 100 million U.S. consumers have conditions that could be treated by Pfizers’ medications covered in this agreement.

The agreement is intended to provide every state Medicaid program in the country with access to MFN drug prices on Pfizer products, which is expected . . .